Download presentation
Presentation is loading. Please wait.
1
Volume 14, Issue 5, Pages 485-496 (May 2015)
Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial The Lancet Neurology Volume 14, Issue 5, Pages (May 2015) DOI: /S (15) Copyright © 2015 The IST-3 collaborative group. Open access article distributed under the terms of CC BY Terms and Conditions
2
Figure 1 Trial profile The Lancet Neurology , DOI: ( /S (15) ) Copyright © 2015 The IST-3 collaborative group. Open access article distributed under the terms of CC BY Terms and Conditions
3
Figure 2 Forest plot showing the adjusted effect of treatment and baseline imaging signs on Oxford Handicap Scale score 0–2 at 6 months Data are adjusted for age, National Institutes of Health Stroke Scale score, and time to randomisation. The Lancet Neurology , DOI: ( /S (15) ) Copyright © 2015 The IST-3 collaborative group. Open access article distributed under the terms of CC BY Terms and Conditions
4
Figure 3 Forest plot showing the adjusted effect of treatment and baseline imaging signs on symptomatic intracranial haemorrhage within 7 days Data are adjusted for age, National Institutes of Health Stroke Scale score, and time to randomisation. The Lancet Neurology , DOI: ( /S (15) ) Copyright © 2015 The IST-3 collaborative group. Open access article distributed under the terms of CC BY Terms and Conditions
5
Figure 4 Forest plot showing the interaction between response to alteplase and early infarct size in previous trials ASPECTS=Alberta Stroke Programme Early CT Signs. ECASS II=European Co-operative Acute Stroke Study-II. IST-3=third International Stroke Trial. NINDS=National Institute of Neurological Disorders and Stroke. PROACT 2=Prolyse in Acute Cerebral Thromboembolism 2. The Lancet Neurology , DOI: ( /S (15) ) Copyright © 2015 The IST-3 collaborative group. Open access article distributed under the terms of CC BY Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.